Bing Zhang
Senior Vice President of Biology Polymed Biopharma
Dr. Bing Zhang obtained his Ph.D. in Biology from Durham University. He has nearly 20 years of drug discovery experiences in both research and project management. Over the course of his career, he has successfully led the advancement of four bispecific antibodies into clinical development with two of them currently in Phase III clinical trials. He joined Polymed as VP in Biology 2021 and raised his rank to SVP. He co-led several Degrader projects and advanced IRAK4 Protac HPB-143 into Phase 1 trial 2026. He currently manages several Degrader Antibody Conjugates projects at Polymed.
Seminars
As Korean biotechs advance from discovery toward clinical development, the transition often exposes critical gaps in technical standards and strategic planning. This workshop will provide actionable guidance on implementing global best practices for assay design, selectivity profiling, and translational alignment, while addressing the unique challenges faced by emerging TPD companies in Asia. Attendees will gain clarity on what global partners expect, how to structure industry standard compliant data packages, and how to better transition into the clinic.
Key Takeaways:
- Exploring the PLK1 bifunctional degrader for the treatment of SCLC and other cancer types
- Discovering the potent PROTACS and degrader antibody conjugates for “undruggable” targets including KRAS G12D, colorectal and pancreatic cancers
- The discovery of clinical-stage BTK degrader, BGB-16673 and overcoming on-target resistance from BTK inhibitors
